US EditionCould this 'average' FTSE 100 stock be one to consider in these difficult times?
Summary by The Motley Fool UK
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Could this 'average' FTSE 100 stock be one to consider in these difficult times?
Since April 2024, the Hikma Pharmaceuticals (LSE:HIK) share price has risen 5%, matching the performance of the FTSE 100. And based on dividends declared over the same period, the stock’s presently yielding 3.2%. The average for the Footsie as a whole is 3.5%. On these measures, the manufacturer of generic, branded and in-licensed medicines, could be described as the ‘most average’ on the index. And in my opinion, there’s nothing wrong with that…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
